Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA. Leyten GH, et al. Among authors: de reijke tm, de jong h. Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15. Eur Urol. 2014. PMID: 23201468
Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer.
Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Schalken JA. Leyten GH, et al. Among authors: de reijke tm, de jong h. Clin Cancer Res. 2015 Jul 1;21(13):3061-70. doi: 10.1158/1078-0432.CCR-14-3334. Epub 2015 Mar 18. Clin Cancer Res. 2015. PMID: 25788493
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA. Van Neste L, et al. Among authors: de reijke tm, de jong h. Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20. Eur Urol. 2016. PMID: 27108162
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
Hendriks RJ, van der Leest MMG, Israël B, Hannink G, YantiSetiasti A, Cornel EB, Hulsbergen-van de Kaa CA, Klaver OS, Sedelaar JPM, Van Criekinge W, de Jong H, Mulders PFA, Crawford ED, Veltman J, Schalken JA, Barentsz JO, van Oort IM. Hendriks RJ, et al. Among authors: de jong h. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1110-1119. doi: 10.1038/s41391-021-00367-8. Epub 2021 May 3. Prostate Cancer Prostatic Dis. 2021. PMID: 33941866 Free PMC article.
Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer.
Visser WCH, de Jong H, Steyaert S, Melchers WJG, Mulders PFA, Schalken JA. Visser WCH, et al. Among authors: de jong h. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):583-589. doi: 10.1038/s41391-022-00562-1. Epub 2022 Jul 9. Prostate Cancer Prostatic Dis. 2022. PMID: 35810263 Free PMC article.
552 results